Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism
Introduction: Dipeptidyl peptidase-4 (DPP4) has been shown to be a functional receptor for MERS-CoV. An interaction between the viral spike protein and DPP4 is thought to facilitate viral entry. We aimed to find out whether sitagliptin, a member of DPP4 inhibitors, would have beneficial effects in C...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bilimsel Tip Yayinevi
2022-06-01
|
| Series: | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| Subjects: | |
| Online Access: | http://floradergisi.org/managete/fu_folder/2022-02/324-334%20Gule%20Cinar.pdf |
| _version_ | 1797917646593720320 |
|---|---|
| author | Güle ÇINAR Satı COŞGUN YAZGAN Atilla Halil ELHAN İrem AKDEMİR KALKAN Ezgi GÜLTEN Mehmet Altay ÜNAL Özgür DEMİR Kemal Osman MEMİKOĞLU Mehmet Serhat BİRENGEL Zeynep Ceren KARAHAN Hasan NAZIR Ebru EVREN Alpay AZAP |
| author_facet | Güle ÇINAR Satı COŞGUN YAZGAN Atilla Halil ELHAN İrem AKDEMİR KALKAN Ezgi GÜLTEN Mehmet Altay ÜNAL Özgür DEMİR Kemal Osman MEMİKOĞLU Mehmet Serhat BİRENGEL Zeynep Ceren KARAHAN Hasan NAZIR Ebru EVREN Alpay AZAP |
| author_sort | Güle ÇINAR |
| collection | DOAJ |
| description | Introduction: Dipeptidyl peptidase-4 (DPP4) has been shown to be a functional receptor for MERS-CoV. An interaction between the viral spike protein and DPP4 is thought to facilitate viral entry. We aimed to find out whether sitagliptin, a member of DPP4 inhibitors, would have beneficial effects in COVID-19 patients.
Materials and Methods: In this single center retrospective study, we evaluated 58 patients of whom 16 were on sitagliptin treatment. Molecular docking studies were performed to identify possible interactions between ACE2 and sitagliptin.
Results: Sitagliptin use shortened the time to clinical recovery about 3.5 and fastened viral clearance more than 5 days. Resolution of all symptoms was achieved on a mean±standard error (SE) of 2.50 ± 0.40 days in sitagliptin (+) group and 5.69 ± 0.61 days in sitagliptin (-) group (Log-rank test, p< 0.001). PCR tests for SARS-CoV-2 resulted negative in mean ± SE of 7.50 ± 0.98 days in sitagliptin (+) and 13.17 ± 1.07 days in sitagliptin (-) group (Log-rank test, p= 0.003). Compared to day 0, CRP, ferritin and D-dimer levels on days three, five, and seven were significantly lower whereas lymphocyte count was higher in sitagliptin (+) group.
Conclusion: Our results suggest that sitagliptin seems to have a potential to be considered for the treatment of COVID-19. |
| first_indexed | 2024-04-10T13:16:39Z |
| format | Article |
| id | doaj.art-27c18c6a6b5948dfa75cd3bb84f323fa |
| institution | Directory Open Access Journal |
| issn | 1300-932X 1308-5115 |
| language | English |
| last_indexed | 2024-04-10T13:16:39Z |
| publishDate | 2022-06-01 |
| publisher | Bilimsel Tip Yayinevi |
| record_format | Article |
| series | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| spelling | doaj.art-27c18c6a6b5948dfa75cd3bb84f323fa2023-02-15T16:12:16ZengBilimsel Tip YayineviFlora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi1300-932X1308-51152022-06-0127232433410.5578/flora.20229816Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the MechanismGüle ÇINAR0https://orcid.org/0000-0002-7635-8848Satı COŞGUN YAZGAN1https://orcid.org/0000-0002-2979-9974Atilla Halil ELHAN2https://orcid.org/0000-0003-3324-248Xİrem AKDEMİR KALKAN3https://orcid.org/0000-0001-5136-9148Ezgi GÜLTEN4https://orcid.org/0000-0003-0248-7716Mehmet Altay ÜNAL5https://orcid.org/0000-0001-8607-5043Özgür DEMİR6https://orcid.org/0000-0001-6555-3579Kemal Osman MEMİKOĞLU7https://orcid.org/0000-0001-7206-3252Mehmet Serhat BİRENGEL8https://orcid.org/0000-0002-5599-6488Zeynep Ceren KARAHAN9https://orcid.org/0000-0001-7727-3363Hasan NAZIR10https://orcid.org/0000-0002-8423-751XEbru EVREN11https://orcid.org/0000-0001-6502-4239Alpay AZAP12https://orcid.org/0000-0001-5035-055XDepartment of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Internal Medicine, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Biostatistics, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, TürkiyeStem Cell Institute Ankara University, Ankara, TürkiyeDepartment of Endocrinology, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Chemistry, Ankara University Faculty of Science, Ankara, TürkiyeDepartment of Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, TürkiyeDepartment of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, TürkiyeIntroduction: Dipeptidyl peptidase-4 (DPP4) has been shown to be a functional receptor for MERS-CoV. An interaction between the viral spike protein and DPP4 is thought to facilitate viral entry. We aimed to find out whether sitagliptin, a member of DPP4 inhibitors, would have beneficial effects in COVID-19 patients. Materials and Methods: In this single center retrospective study, we evaluated 58 patients of whom 16 were on sitagliptin treatment. Molecular docking studies were performed to identify possible interactions between ACE2 and sitagliptin. Results: Sitagliptin use shortened the time to clinical recovery about 3.5 and fastened viral clearance more than 5 days. Resolution of all symptoms was achieved on a mean±standard error (SE) of 2.50 ± 0.40 days in sitagliptin (+) group and 5.69 ± 0.61 days in sitagliptin (-) group (Log-rank test, p< 0.001). PCR tests for SARS-CoV-2 resulted negative in mean ± SE of 7.50 ± 0.98 days in sitagliptin (+) and 13.17 ± 1.07 days in sitagliptin (-) group (Log-rank test, p= 0.003). Compared to day 0, CRP, ferritin and D-dimer levels on days three, five, and seven were significantly lower whereas lymphocyte count was higher in sitagliptin (+) group. Conclusion: Our results suggest that sitagliptin seems to have a potential to be considered for the treatment of COVID-19.http://floradergisi.org/managete/fu_folder/2022-02/324-334%20Gule%20Cinar.pdfcovid-19dpp4 inhibitorsace2sitagliptinsars-cov-2 |
| spellingShingle | Güle ÇINAR Satı COŞGUN YAZGAN Atilla Halil ELHAN İrem AKDEMİR KALKAN Ezgi GÜLTEN Mehmet Altay ÜNAL Özgür DEMİR Kemal Osman MEMİKOĞLU Mehmet Serhat BİRENGEL Zeynep Ceren KARAHAN Hasan NAZIR Ebru EVREN Alpay AZAP Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi covid-19 dpp4 inhibitors ace2 sitagliptin sars-cov-2 |
| title | Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism |
| title_full | Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism |
| title_fullStr | Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism |
| title_full_unstemmed | Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism |
| title_short | Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism |
| title_sort | repurposing sitagliptin for covid 19 in adults clinical benefits and an approach for the mechanism |
| topic | covid-19 dpp4 inhibitors ace2 sitagliptin sars-cov-2 |
| url | http://floradergisi.org/managete/fu_folder/2022-02/324-334%20Gule%20Cinar.pdf |
| work_keys_str_mv | AT gulecinar repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT satıcosgunyazgan repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT atillahalilelhan repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT iremakdemirkalkan repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT ezgigulten repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT mehmetaltayunal repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT ozgurdemir repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT kemalosmanmemikoglu repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT mehmetserhatbirengel repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT zeynepcerenkarahan repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT hasannazir repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT ebruevren repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism AT alpayazap repurposingsitagliptinforcovid19inadultsclinicalbenefitsandanapproachforthemechanism |